Loading stock data…
SMTI
$19.73+0.74 (+3.90%)
Market ClosedLast close May 1
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Sanara MedTech Inc. in the Healthcare sector is trading at $19.73. The stock is currently near its 52-week low of $16.05, remaining 19.9% below its 200-day moving average. Technical signals show neutral RSI of 63 and bullish MACD crossover, explaining why SMTI maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 63) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$19.73
Potential Upside
5%
Whystock Fair Value$20.72
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolys...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$182.97M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.10
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-632.53%
Volume
Today's trading volume
31,312
Recent News
What Makes Sanara Medtech (SMTI) A Compelling Risk-Reward Opportunity?
White Brook Capital Partners, an investment management firm, released its first-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter indicated that the first quarter of 2026 was a turnaround period. During this quarter, US military actions against Iran and developments in AI dominated economic discussions. These military interventions created a […]
How The Sanara MedTech (SMTI) Story Is Shifting With New Targets And Growth Assumptions
Sanara MedTech’s fair value target has shifted from $36 to $34, a $2 adjustment that resets expectations around what investors might be willing to pay for the shares. Analysts link this move to a more balanced view that weighs the long term growth story against practical execution risks laid out in recent commentary. As you read on, you will see how this updated target fits into the evolving Street narrative and what to watch next in the story. Analyst Price Targets don't always capture the...
Sanara MedTech Inc. Q4 2025 Earnings Call Summary
Moby summary of Sanara MedTech Inc.'s Q4 2025 earnings call
Sanara MedTech Inc (SMTI) Q4 2025 Earnings Call Highlights: Record Revenue and Strategic Growth ...
Sanara MedTech Inc (SMTI) reports a milestone year with over $100 million in net revenue and outlines strategic priorities for continued growth in 2026.
Sanara MedTech Q4 Earnings Call Highlights
Sanara MedTech (NASDAQ:SMTI) reported fourth-quarter and full-year 2025 results highlighting record annual revenue, improved profitability, and progress in its transition to a “pure-play” surgical company following the wind-down of its Tissue Health Plus (THP) segment. Full-year results top $100 mi